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Abstract
Background
Alpha-1 antitrypsin deficiency (AATD) is the most common hereditary disorder in adults, but
is under-recognized. In Spain, the number of patients diagnosed with AATD is much lower
than expected according to epidemiologic studies. The objectives of this study were to
assess the frequency and determinants of testing serum α1-antitrypsin (AAT) levels in
COPD patients, and to describe factors associated with testing.
Methods
EPOCONSUL is a cross-sectional clinical audit, recruiting consecutive COPD cases over
one year. The study evaluated serum AAT level determination in COPD patients and associ-
ations between individual, disease-related, and hospital characteristics.
Results
A total of 4,405 clinical records for COPD patients from 57 Spanish hospitals were evalu-
ated. Only 995 (22.5%) patients had serum AAT tested on some occasion. A number of
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patient characteristics (being male [OR 0.5, p < 0.001],55 years old [OR 2.38, p<0.001],
BMI21 kg/m2 [OR 1.71, p<0.001], FEV1(%)<50% [OR 1.35, p<0.001], chronic bronchitis
[OR 0.79, p < 0.001], Charlson index 3 [OR 0.66, p < 0.001], or history or symptoms of
asthma [OR 1.32, p<0.001]), and management at a specialized COPD outpatient clinic [OR
2.73,p<0.001] were identified as factors independently associated with ever testing COPD
patients for AATD. Overall, 114 COPD patients (11.5% of those tested) had AATD. Of them,
26 (22.8%) patients had severe deficiency. Patients with AATD were younger, with a low
pack-year index, and were more likely to have emphysema (p<0.05).
Conclusion
Testing of AAT blood levels in COPD patients treated at outpatient respiratory clinics in
Spain is infrequent. However, when tested, AATD (based on the serum AAT levels100
mg/dL) is detected in one in five COPD patients. Efforts to optimize AATD case detection in
COPD are needed.
Introduction
Alpha-1antitrypsin deficiency (AATD) is the most common hereditary disorder in adults,
characterized by impaired or defective production of the α1-antitrypsin (AAT) protein in the
liver, which is associated with an increased risk of developing pulmonary emphysema and
liver disease.
Recommendations of healthcare institutions such as the World Health Organization
(WHO)[1], the Spanish National Guidelines for Chronic Obstructive Pulmonary Disease
(GesEPOC)[2] and the American and European Thoracic/Respiratory Societies (ATS/ERS)
[3,4] indicate that all chronic obstructive pulmonary disease (COPD)patients should be tested
for AATD at least once during their lifetime. However, the real-life implementation of these
clinical practice guidelines (CPG) is low [5]. AATD remains to be underdiagnosed despite the
possibility available to determine AAT levels in blood and clinical guidelines recommenda-
tions [6,7].
The first step in the diagnosis of the deficiency is the determination of serum levels of AAT.
In case of serum levels below the reference values, the next step will be the identification of the
phenotype by immunoelectrophoresis or genotyping of the most frequent deficient alleles,
according of the protocol of the local reference laboratory [8].
It is estimated that up to 2% of cases of COPD are associated with AATD. In particular, epi-
demiological studies in Spain estimate a total of 14,500 individuals with severe homozygous
(PIZZ) deficiency [9], but only around 350 have been identified [10], suggesting that adher-
ence to recommendations is poor. Potential benefits of case detection in all COPD patients
include lifestyle recommendations (smoking prevention or cessation, avoiding high-risk occu-
pations, limiting alcohol intake), identification of at-risk family members, genetic counselling
and consideration for earlier augmentation therapy [4]. Understanding factors associated with
better adherence to CPG recommendations to identify AATD in COPD is important in deter-
mining the possible reasons why such a delay in the diagnosis of AATD still exists.
The objective of our work was to investigate the frequency of determining AAT levels in
COPD patients treated at outpatient respiratory clinics in Spain and to describe factors associ-
ated with AAT testing. We also aimed to study to determine the frequency of serum levels
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below the reference values of AAT in COPD patients treated at outpatient respiratory clinics
in whom the test is performed and to describe clinical characteristics and data on referrals for
diagnostic procedures carried out for COPD evaluation.
Methods
The methodology of the EPOCONSUL audit has been extensively described elsewhere [11].
Briefly, the COPD audit promoted by the Spanish Society of Pulmonary and Thoracic Surgery
(SEPAR) was designed to evaluate clinical practice as well as clinical and organizational factors
related to managing patients with COPD across Spain. It was designed as an observational
cross-sectional study. Recruitment was intermittent over a year (May 2014–May 2015). Every
2 months, each investigator recruited the clinical records of the first 10 patients identified as
being diagnosed with COPD and seen in the outpatient respiratory clinic. Subsequently, the
patients identified were reevaluated to determine if they met the inclusion/exclusion criteria
described in S1 Table. Of the 175 public hospitals in the National Health System invited by
SEPAR, 59 participated (33.3%). The estimated reference population for the EPOCONSUL
study was 18,104,350 inhabitants, representing 39% of the Spanish population. The distribu-
tion of hospitals in the different regions and participating investigators are included in S1
Appendix.
The information collected was historical in nature for the clinical data of the last and previ-
ous visits, and information about hospital resources was concurrent. Data from this study in
S1 File.
In order to compare hospitals, they were divided into two types of center according to their
size (small or large) as measured by: the number of beds per center500, the number of inpa-
tient respiratory beds20, the number of pulmonology staff members5, and the number of
annual outpatient respiratory visits10,000. All the criteria must be met to be considered
large.
In order to evaluate the degree of current CPG implementation of the recommendation
(determining AAT blood levels in all COPD patients), the cases audited from 57 hospitals with
available AAT blood level determination were analyzed.
Based on the serum AAT levels, individuals were classified as follows: no deficiency: AAT
>100 mg/dL; intermediate deficiency: AAT between 51 mg/dL and 100 mg/dL; and severe
deficiency: AAT50 mg/dL [12].
The patients with clinical/radiological or functional characteristics of emphysema were
classified as emphysema phenotype.
The protocol was approved by the Ethics Committee of the Hospital Clı´nico San Carlos
(Madrid, Spain; internal code 14/030-E). Additionally, according to current research laws in
Spain, the ethics committee at each participating hospital evaluated and agreed to the study
protocol. The need for informed consent was waived due to the non-interventional nature of
the study, the anonymization of data and the need to blindly evaluate the clinical performance.
This circumstance was clearly explained in the protocol, and the ethical committees approved
this procedure. To avoid modifications to the usual clinical practice and preserve the blinding
of the clinical performance evaluation, the medical staff responsible for the outpatient respira-
tory clinic was not informed about the audit. Data was entered remotely at each participating
location to a centrally-controlled server.
Statistical analysis
Qualitative variables were summarized by their frequency distribution and quantitative vari-
ables by their median, interquartile range (IQR) and minimum–maximum. The differences
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between hospital resources and characteristics according to size (small vs large) were evaluated
using χ2 tests for categorical data, while the non-parametric Mann-Whitney test was used for
continuous data. With regard to missing data, after performing data cleansing to identify and
correct missing and extremely unlikely values, the data was included in the analysis as missing
information.
The association between each independent variable (patient characteristics, hospital
resources and work organization) and the dependent variable AAT level determination was
assessed by calculating the crude odds ratio (OR) via mixed effect logistic regression model.
Each model included a random effect to account for the correlation between individuals within
the same hospital. A multivariable mixed effect model was fitted in order to evaluate the inde-
pendent effect of the selected variables. Candidate predictors with a value of p< 0.10 in the
univariate analysis were accepted for inclusion in the multilevel multivariate analysis. Vari-
ables were removed from the model when the p-value exceeded 0.10 and were kept in the final
model when less than 0.05.
All analyses were performed using STATA 12.0 software. Statistical significance was
assumed as p< 0.05.
Results
Population
A total of 4408 patients audited from 57 hospitals were included in the analysis. The sampling
process was detailed in an epidemiology flow chart and described in Fig 1. Of the analyzed
cohort, only 995 (22.5%) patients underwent AAT determination (Fig 2).
Characteristics of the individuals tested for AAT concentrations
The mean AAT plasma level was 143 (SD 41.6) mg/dL. In total, 114 patients (11.5% of the
individuals tested) had the serum AAT levels 100 mg/dL. Of them, 88 (77.2%) patients
had the serum AAT levels between 51 mg/dL and 100 mg/dL (might be considered an inter-
mediate AATD), while 26 (22.8%) patients had the serum AAT levels 50mg/dl (a severe
AATD).
Patients with AATD (based on the serum AAT levels100 mg/dL) were younger than indi-
viduals with normal AAT levels (61.7 years vs 66 years, p<0.001), with a lower pack-year index
(39 versus 45, p<0.001), were more likely to have characteristics of emphysema (34.3% versus
18.9%, p = 0.003), have less dyspnea and were less likely to have a Charlson index3 (23.7% vs
39.7%,p<0.001). During follow-up in patients with AATD, diffusing capacity (78.9% vs 68.7%,
p = 0.024) and lung volume (74.6% vs 62.7%, p = 0.013) were more commonly measured and
the 6-minute walk test more frequently carried out (48.2% vs 38.1%, p = 0.038), as summarized
in Table 1.
Center characteristics
The hospital characteristics and respiratory unit resources are summarized in S2 Table. Large
hospitals constituted 56% of centers. The majority of participating centers were public (93%),
university hospitals (86%) and had a pulmonology resident available (70.2%). Although the
larger hospitals had more staff (median 13; CI 95% 10–16 vs median 6; CI 95% 2–8, p <0.001),
the availability of respiratory unit resources was similar, including AATD genotyping (71.9%
vs 68%, p = 0.751). There were few centers with a specialized COPD outpatient clinic (47.4%),
regardless of hospital size.
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Fig 2. Distribution of AAT level determination in the blood. Of the analyzed cohort, only 995 (22.5%) patients underwent AAT
determination.
https://doi.org/10.1371/journal.pone.0198777.g002
Fig 1. The sampling process is described in a STROBE flow chart. A total of 17,893 clinical records of patients
treated in outpatient respiratory clinics were evaluated during the study period and 5,726 clinical records of patients
presumably diagnosed with COPD were selected. Of them, 4,508 patients were audited from 59 hospitals, for having all
the inclusion criteria and none of the exclusion criteria. A total of 4408 patients audited from 57 hospitals with
available AAT blood level determination were included for this retrospective analysis of alpha-1 antitrypsin deficiency
diagnosis.
https://doi.org/10.1371/journal.pone.0198777.g001
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Center and respiratory unit resource characteristic sand their association
with AAT testing in COPD patients
The majority of center-level variables were not associated with adherence to the recommenda-
tion to test for AAT in patients with a diagnosis of COPD, except the number of annual outpa-
tient respiratory visits10,000 (OR 2.18, p = 0.05) and the availability of a specialized COPD
outpatient clinic (OR 1.91, p = 0.021). Table 2 describes the logistic regression univariate anal-
ysis with the variables related to centers.
Sociodemographic and clinical patient characteristics and their association
with AAT testing in COPD patients
Table 3 describes the characteristics of the evaluated patients and the association with AAT
testing in COPD patients (logistic regression univariate analysis). A large number of the
Table 1. Characteristics of COPD patients tested for AAT, and diagnostic procedures conducted during the follow-up for medical evaluation according to pres-
ence/absence of AATD.
Characteristics of the patient No AATD
(AAT >100mg/dl)
(n = 881)
AATD
(AAT 100mg/dl)
(n = 114)
P
Serum AAT level (mg/dl), m (SD) 149.95 (34.9) 56.18 (25)
Age (years), m (SD) 66.05 (9.6) 61.73 (10.2) <0.001
Sex (female), (%) 21.1 19.3 0.654
Current smoker, (%) 25.4 21.9 0.417
Smoking pack-year, median (IQR) 45 (33–70) 39 (25–55) <0.001
BMI kg/m2, m (SD) 27.12 (5.3) 26.70 (5.2) 0.435
Dyspnea (mMRC) 0.050
0–1 (%) 32.7 20.2
2 (%) 42.5 51.8
Charlson index3, (%) 39.7 23.7 0.001
Chronic bronchitis, (%) 38.6 33.3 0.276
Emphysema phenotype, (%) 18.9 34.3 0.003
History of asthma or symptoms suggestive of asthma, (%) 34.1 28.9 0.277
COPD Phenotype 0.146
Non-exacerbator, (%) 36.2 32.5
Exacerbator, (%) 20.9 28.9
Number of hospitalizations in the last year, (%) 0.615
0 77.8 79.8
1 22.2 20.2
%predicted post-BD FEV1, m (SD) 48.56 (18.3) 48.38 (18.9) 0.921
<50%, (%) 55.7 50.9
BODE, m (SD) 4.26 (2.0) 4.66 (1.6) 0.303
Long-term oxygen therapy, (%) 26.3 38.6 0.006
Diagnostic procedures conducted during the follow-up for COPD evaluation No AATD
(AAT >100mg/dl)
(n = 881)
AATD
(AAT 100mg/dl)
(n = 114)
P
Diffusing capacity measured, (%) 68.7 78.9 0.024
Lung volumes measured, (%) 62.7 74.6 0.013
6-minute walk test performed, (%) 38.1 48.2 0.038
BODE index registered, (%) 20.4 28.1 0.061
Chest CT scan done, (%) 73.4 80.7 0.095
Non-exacerbator: patients with 0 or 1 exacerbation in the previous year; Exacerbator: patients who experienced at least two exacerbations in the previous year.
https://doi.org/10.1371/journal.pone.0198777.t001
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patient-level variables were associated with AAT level determination, such as being male (OR
0.47, p<0.001), age55 years old (OR 3.16, p<0.001), pack-year index (10 pack-years) (OR
0.97, p<0.043),being an active smoker (OR 1.30, p = 0.004), BMI21 (OR 2.21, p<0.001),
Charlson index3 (OR 0.57, p<0.001), symptoms of asthma (OR 1.55, p<0.001), and a FEV1
<50% (OR 1.33, p<0.001). Being treated at a specialized COPD outpatient clinic was associ-
ated with a higher likelihood of being tested for AAT (OR 2.94, p<0.001).
Multilevel analysis of factors associated with AAT testing in COPD
patients
In the adjusted model, summarized in Table 4, being55 years old (OR 2.38, p<0.001), hav-
ing a BMI21 (OR 1.71, p<0.001), FEV1<50% (OR 1.75, p<0.001), history or symptoms of
asthma (OR 1.32, p<0.001) and being treated at a specialized COPD outpatient clinic (OR
2.73, p<0.001) were positively associated with AAT testing, while Charlson index3 (OR 0.66,
p<0.001), being male (OR 0.55, p<0.001) and chronic bronchitis criteria (OR 0.79, p<0.001)
showed a statistically significant negative association. Some unrecorded values (COPD pheno-
type missing, dyspnea missing, or level of dyspnea not referred to) showed a significant nega-
tive association.
Discussion
Our results have shown that only 22.5% of COPD patients followed up in hospitals in Spain
have a AAT value recorded in their clinical records. This study provides data for the first time
about the frequency with which AAT is tested in COPD patients treated in outpatient respira-
tory clinics in Spain, as well as factors associated with performing this test.
Table 2. Characteristics of participating hospitals and respiratory unit resources, by COPD patients with/without serum AAT levels tested.
Centers All patients
(n = 4,408)
COPD patients with serum AAT
levels tested
(n = 995)
COPD patients without serum AAT
levels tested
(n = 3,413)
OR (95%CI) p
Large hospital, (%) 62.9 67.4 61.6 1.41 (0.79–2.50) 0.240
University hospital, (%) 88 88.5 87.9 1.02 (0.44–2.32) 0.962
Beds per center500, (%) 71.9 74.2 71.2 1.18 (0.64–2.17) 0.581
Respiratory ward not available, (%) 11.5 8.1 12.5 Reference
Respiratory ward<20 beds 13.4 12.9 13.5 1.46 (0.49–4.31) 0.485
Respiratory ward20 beds 75 78.9 73.8 1.58 (0.68–3.67) 0.278
Number of pulmonology staff members5, (%) 78.9 80.2 78.5 0.80 (0.35–1.86) 0.620
Pulmonology residents present, (%) 74.1 75.2 73.8 1.01 (0.53–1.91) 0.963
Number of annual outpatient respiratory
visits 10,000, (%)
88.8 93.3 87.4 2.18 (0.99–4.79) 0.05
 15 minutes of follow-up at general outpatient
respiratory visit, (%)
41.9 42.9 417 1.16 (0.65–2.06) 0.618
AATD genotyping availability, (%) 74.1 77.3 73.2 1.41 (0.75–2.65) 0.284
Specialized COPD outpatient clinic available, (%) 52.5 61.4 50 1.91 (1.10–3.32) 0.021
Outpatient respiratory nursing clinic availability,
(%)
45.9 50.4 44.5 1.32 (0.75–2.33) 0.333
Inhalation technique educational program
available, (%)
29.9 33.8 28.8 1.23 (0.67–2.28) 0.494
The necessary criteria to consider a hospital large are: the number of beds per center500, the number of inpatient respiratory beds20, the number of pulmonology
staff members5, and the number of annual outpatient respiratory visits10,000.
https://doi.org/10.1371/journal.pone.0198777.t002
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One of most relevant aspects with regard to AATD is that, despite the fact it is considered
the most common hereditary disease in adults and is potentially fatal, the disease continues to
be underdiagnosed around the world [12,13].
In Spain, the S and Z allele frequency are estimated to be 104/1.000 and 17/1.000 respec-
tively, which, taking the Spanish population into account, means that 14.500 people have a ZZ
phenotype and 175.000 have an SZ phenotype [14,15]. These data places Spain as the country
Table 3. Characteristics of COPD patients and hospital care variables according to whether serum AAT levels were determined to detect cases of AATD (logistic
regression bivariate analysis).
All patients
(n = 4.408)
COPD patients with serum AAT
levels tested
(n = 995)
COPD patients without serum AAT
levels tested
(n = 3,413)
OR (95%CI) p
Sex (male), (%) 85.7 79 87.6 0.47 (0.38-.58) <0.001
Age (years), m (SD) 69.66 (9.77) 65.55 (9.82) 70.86 (9.42) 0.94 (0.93–0.95) <0.001
Patients55 (%) 8.6 15.87 6.50 3.16 (2.47–4.04) <0.001
Smoking pack-year, m (SD) 55.9 (33.74) 54.10 (32.06) 56.46 (34.19) 0.97 (0.95–0.99) 0.043
Active smokers, (%) 23.3 25 22.8 1.30 (1.08–1.55) 0.004
BMI kg/m2, m (SD) 28.03 (5.45) 27.07 (5.37) 28.31 (5.45) 0.94 (0.92–0.95) <0.001
21 (%) 7.1 11.1 6.9 2.21 (1.68–2.91) <0.001
Charlson index3, (%) 45.2 37.8 47.4 0.57 (0.49–0.67) <0.001
Dyspnea (mMRC)
0–1, (%) 27 31.2 25.7 Reference
2, (%) 41.1 43.5 40.4 0.88 (0.73–1.07) 0.797
Missing, (%) 13.4 10.6 14.2 0.43 (0.32–0.58) <0.001
Level of dyspnea not referred to, (%) 18.3 14.5 19.5 0.50 (0.38–0.66) <0.001
Chronic bronchitis, (%) 41.4 38 42.4 0.85 (0.72–1.00) 0.056
History of asthma, or symptoms suggestive
of asthma,(%)
26.5 33.5 24.5 1.55 (1.29–1.86) <0.001
Emphysema phenotype, (%) 18.7 20.8 17.8 1.27 (0.97–1.66) 0.079
%predicted post-BD FEV1, m (SD) 50.96 (17.7) 48.54(18.3) 51.66 (17.4) 0.99 (0.98–1) <0.001
<50% 49 55.1 47.3 1.33 (1.14–1.56) <0.001
COPD Phenotype
Non-exacerbator, (%) 26.7 35.7 24 Reference
Exacerbator, (%) 18.6 21.8 17.7 0.84 (0.67–1.04) 0.119
Missing, (%) 54.6 42.4 58.1 0.45 (0.37–0.55) <0.001
Number of hospital admissions in the last
year1, (%)
23.3 22 23.7 0.91 (0.75–1.10) 0.367
Chronic colonization, (%) 6 5.9 6 1.15 (0.83–1.60) 0.381
Triple or quadruple inhaled therapy, (%) 66.9 61 65.7 1.18 (1.00–1.39) 0.039
Long-term oxygen therapy, (%) 26.6 27.7 26.2 1.05 (0.88–1.26) 0.544
Home ventilation, (%) 7.5 6.8 7.9 0.69 (0.50–0.96) 0.027
Type of respiratory outpatient clinic: <0.001
general clinic, (%)
specialized COPD clinic, (%)
47.4 38.6 49.9 1
52.6 61.4 50.1 2.94 (2.26–3.83)
Respiratory care follow-up (years), median
(IQR)
4(2–7) 4 (2–6) 4 (2–7) 1.00 (0.99–1.00) 0.382
Non-exacerbator: patients with 0 or 1 exacerbation in the previous year; Exacerbator: patients who experienced at least two exacerbations in the previous year; Dyspnea
not quantified: level of dyspnea not referred to. Abbreviations: BMI: body mass index; mMRC, modified Medical Research Council; %predicted post-BD FEV1, percent
predicted post-bronchodilator FEV1; GesEPOC: Spanish National Guidelines for COPD. IQR: interquartilerange.
https://doi.org/10.1371/journal.pone.0198777.t003
Testing serum alpha-1 antitrypsin levels in COPD outpatients
PLOS ONE | https://doi.org/10.1371/journal.pone.0198777 June 28, 2018 8 / 14
with the second highest number of severe AATD in Europe after Italy [14]. However, the
prevalence of AATD clashes with the reality of the Spanish Registry of Patients with Alpha-1
Antitrypsin Deficit (REDAAT) that only registered 348 individuals PiZZ and 100 PiSZ, rep-
resenting less than 1% of existing cases [10,16]. Additionally, studies have estimated a 5–10
year delay between the diagnoses of COPD and AATD in Spain [6,13].
The underdiagnosis of AATD is a current reality, which is supported by the results of this
study, making it clear that the majority of COPD patients treated in outpatient respiratory
clinics in Spain did not undergo AAT determination in blood in spite of having prolonged fol-
low-up. These data reflects the inadequate clinical practice with regard to detecting cases of
AATD in an at-risk group such as COPD patients and does not adhere to CPG recommenda-
tions, which calls for determining AAT levels in blood for all patients with a COPD diagnosis
[1–4].
In our study, we found a rate of only 22.6 determinations of AAT levels in blood per 100
COPD patients treated in an outpatient respiratory clinic in centers where this test was avail-
able, signaling a lack of awareness and understanding of AATD among many doctors, who
forget to request serum AAT levels in the majority of their COPD patients as the main deter-
mining factor in this underdiagnosis. This poor awareness about AATD is also present in pri-
mary care. A recent population-based study with data from electronic clinical records from
primary care in Catalonia revealed a frequency of AAT testing of only 4–6 determinations per
10,000 inhabitants, both in children and adults between the years 2007 and 2011. This study
also showed that patients with detected AATD were not always referred to a specialist [17].
Studies on the level of training for AATD have shown poor knowledge among doctors,
even those interested in respiratory diseases [18], identifying the erroneous perception of the
high cost of the test or the need to refer the patients to other specialists in order to make the
diagnosis as the main reasons for not determining AAT levels in blood [19]. In a survey done
Table 4. Multivariate logistic regression to identify independent factors associated with testing of COPD patients
for serum AAT levels to detect cases of AATD.
Variable OR (95%CI) p
Sex (male) 0.55 (0.44–0.69) <0.001
Age55(years) 2.38 (1.82–3.13) <0.001
Charlson index3 0.66 (0.55–0.78) <0.001
Chronic bronchitis 0.79 (0.66–0.95) <0.001
Medical history of asthma, or symptoms suggestive of asthma 1.32 (1.08–1.61) <0.001
Dyspnea (mMRC)
0–1, (%) 1
2, (%) 0.86 (0.68–1.07) 0.185
Missing, (%) 0.47 (0.29–0.64) <0.001
Level of dyspnea not referred to,(%) 0.53 (0.37–0.71) <0.001
BMI21 kg/m2 1.71 (1.27–2.29) <0.001
% predicted FEV1<50% 1.35 (1.13–1.62) <0.001
COPD phenotype
Non-exacerbator, (%) 1
Exacerbator, (%) 0.91 ((0.55–1.17) 0.495
Missing, (%) 0.59 (0.35–0.73) <0.001
Managed at a specialized COPD outpatient clinic 2.73 (2.07–3.61) <0.001
Triple or quadruple inhaled therapy, (%) 1.17 (0.90–0.98) 0.09
Home ventilation, (%) 0.70 (0.60–0.98) 0.04
https://doi.org/10.1371/journal.pone.0198777.t004
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in Spain and Portugal, only 14% of doctors surveyed referred to having “a good level” of
knowledge on AATD and only 55% of pulmonologists knew the AAT threshold considered to
be a severe deficiency, which would indicate that many doctors’ knowledge about how to
make the diagnosis is insufficient. More importantly, only 27% of respiratory specialists
declared to systematically test all their COPD patients for AAT [20].
With regard to the factors associated with determining testing for AAT found in our study,
it is striking that the majority were patient-level variables. These associated factors would be
consistent with the typical clinical characteristics classically attributed to AATD-related
COPD and could be summarized as “a young adult with progressive dyspnea and developed
emphysema despite lower tobacco exposure”. This could reflect suspected AATD in a patient
with a “typical” profile, thus a focused case-detection is done. However, with only these crite-
ria, multiple other types of patients with less typical presentation would not be diagnosed. For
this reason, since 1997, the WHO [1] consensus document has recommended that AAT con-
centrations be determined in all COPD patients at least once in their lives, a recommendation
maintained in GesEPOC [2] and international CPG (ATS/ERS) [3,4].
It is also important to consider that being treated in a clinic specialized in COPD was asso-
ciated with a higher likelihood of determining AAT levels in blood in our study. This was an
interesting result that could be related to a higher awareness or interest among professionals
treating patients in specialized clinics, or due to the use of electronic medical registries.
Although patients in whom AAT was determined came from centers with a higher volume
of patients and greater availability of clinics specialized in COPD, none of the characteristics of
the center or pulmonology unit resources were maintained as independent factors associated
with testing for AATD in the multivariate analysis.
With regard to the diagnosis of AATD, in Spanish screening or case-detection programs in
COPD patients, such as that done in 2005 by de la Roza et al. where, out of 971 samples, 62
(6.4%) had low levels of AAT and only 4 patients had a severe deficiency [21], or the IDDEA
project (Information and Detection of Alpha-1-Antitrypsin Deficit) carried out in 2008 by the
REDAAT in Primary Care, where of the 596 samples from COPD patients, AAT levels < 60
mg/dl were detected in only 6 (1.1%) [22]. However, in another study conducted in Italy, of a
total of 1841 patients, 151 (8.2%) were identified as having a severe deficiency [23]. This dis-
parity in AATD detection rates is likely due to the inclusion criteria of the study populations.
In our analysis, though we find 2.61 cases of severe AATD (based on the serum AAT levels
50 mg/dL) for every 100 AAT determinations, that can consider higher, but it is necessary to
remember that individuals tested for AAT concentrations was not systematic and is affected
by the choice of the clinicians. Patients identified with AATD, based on the serum AAT levels
100 mg/dL, were younger, with less tobacco use and clinical characteristics of emphysema.
However, there were no differences in airflow limitation severity or BODE index, which sug-
gests a late diagnosis of AATD.
It is of note that more specific respiratory function diagnostic tests, such as lung volume
measurement, diffusing tests and the 6-minute walking test were more commonly requested
in patients with AATD.
Our study has some strengths and limitation. The main strength is the sample size, which
accounts for 39% of the Spanish population. Nevertheless, the limitations to be considered are
the fact that the centers were not randomly selected and were chosen based on having partici-
pated previously in COPD clinical audits and their interest in the study. Additionally, as in all
clinical audits, despite inclusion methodology and periodic supervision of the database, some
of the values were not included as they were not available. We must also mention the possible
limitation in the diagnosis of the deficiency of AAT only based on concentration of the protein
in blood, that might account for temporary deficiency due to liver diseases, low-protein diet,
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hormonal unbalance. Too we must keep in mind that, as an acute phase reactant, infectious or
inflammatory processes may alter AAT determination [24], thus normal or high values may be
detected in individuals with an intermediate deficiency. However, despite these limitations,
the sample included is likely representative of medical attention for patients with COPD in
outpatient respiratory clinics in Spain.
Conclusions
Testing for AAT in COPD patients treated in outpatient respiratory clinics is done infre-
quently. The presence of clinical characteristics typical of AATD-related COPD is a factor
associated with testing, which suggests that a selective search strategy is used in clinical prac-
tice, despite what is recommended in current guidelines. Additionally, being treated in a clinic
specialized in COPD is a factor associated with greater frequency in determining AAT, which
could be explained by the greater interest and knowledge among professionals.
Determining AAT in all patients with COPD is the key to improving underdiagnosis and
achieving early-stage diagnosis. As a result, it is necessary to establish training and awareness
programs for healthcare professionals and to use electronic medical records in usual clinical
practice as support tools to avoid variability and improve quality of care. Efforts to optimize
AATD case detection in COPD are needed.
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